Mendt and colleagues established a standard operating procedure to generate engineered exosomes which had the ability to target oncogenic Kras (iExosomes), and was confirmed to suppress oncogenic Kras and increase the survival of mouse models with pancreatic cancer, which laid the foundation for exosomes in the targeted therapy of NSCLC [109]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.